Project Grant HT94252310411
Award Date
7/1/23
Completion Date
6/30/25
Dollars Obligated
$499K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This federal Project Grant award of $1,117,328.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research on proteomic biomarkers for amyotrophic lateral sclerosis (ALS) disease prognosis and progression monitoring. The award recipient, The University of Queensland in Australia, will conduct this research project from April 1, 2025, through March 31, 2027. The project aims to develop innovative...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
This $749,995 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of gene therapies for the targeted degradation of the TDP-43 protein to treat Amyotrophic Lateral Sclerosis (ALS) at Macquarie University in Australia. The project aims to advance therapeutic approaches for this neurodegenerative disease. Macquarie University, a non-profit educational institution, will conduct the research over a...
This $932,498 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to develop a non-invasive central nervous system (CNS) delivery method for immunocytokines to expand regulatory T cells (Tregs) and treat amyotrophic lateral sclerosis (ALS). The award recipient, the Regents of the University of Michigan, will leverage its expertise in biomedical research to conduct this cutting-edge...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This federal Project Grant award of $798,272.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at The Johns Hopkins University to test the use of Wnt inhibitors as a therapeutic for reversing TDP-43 dysfunction in amyotrophic lateral sclerosis (ALS). The award period runs from March 15, 2025 to March 14, 2027 and will fund sophisticated biomedical research aimed at developing innovative treatments for this...
This federal Project Grant award of $2,180,261.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is funding a Phase 1C study of Prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with amyotrophic lateral sclerosis (ALS). The award period is from April 1, 2025 to March 31, 2027, and the project is being conducted by Projenx Inc., a small disadvantaged business located in New York, NY. The study aims to evaluate the...